AR082850A1 - Aminopirazoloquinazolinas - Google Patents

Aminopirazoloquinazolinas

Info

Publication number
AR082850A1
AR082850A1 ARP110102670A ARP110102670A AR082850A1 AR 082850 A1 AR082850 A1 AR 082850A1 AR P110102670 A ARP110102670 A AR P110102670A AR P110102670 A ARP110102670 A AR P110102670A AR 082850 A1 AR082850 A1 AR 082850A1
Authority
AR
Argentina
Prior art keywords
group
nrhc
alkyl
link
case independently
Prior art date
Application number
ARP110102670A
Other languages
English (en)
Spanish (es)
Inventor
Matthias Treu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR082850A1 publication Critical patent/AR082850A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP110102670A 2010-07-23 2011-07-22 Aminopirazoloquinazolinas AR082850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10170683 2010-07-23

Publications (1)

Publication Number Publication Date
AR082850A1 true AR082850A1 (es) 2013-01-16

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102670A AR082850A1 (es) 2010-07-23 2011-07-22 Aminopirazoloquinazolinas

Country Status (23)

Country Link
US (1) US8735386B2 (enExample)
EP (1) EP2595987B1 (enExample)
JP (1) JP5991974B2 (enExample)
KR (1) KR20130132394A (enExample)
CN (1) CN103097388A (enExample)
AP (1) AP2012006640A0 (enExample)
AR (1) AR082850A1 (enExample)
AU (1) AU2011281504A1 (enExample)
BR (1) BR112013000107A2 (enExample)
CA (1) CA2803467A1 (enExample)
CL (1) CL2012003745A1 (enExample)
CO (1) CO6670575A2 (enExample)
EA (1) EA201201661A1 (enExample)
EC (1) ECSP13012448A (enExample)
GE (1) GEP20156289B (enExample)
MA (1) MA34389B1 (enExample)
MX (1) MX2013000821A (enExample)
PE (1) PE20131143A1 (enExample)
PH (1) PH12013500152A1 (enExample)
SG (1) SG187548A1 (enExample)
TW (1) TW201217380A (enExample)
UY (1) UY33526A (enExample)
WO (1) WO2012010704A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110585A1 (en) 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
ES2724331T3 (es) * 2013-11-15 2019-09-10 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso
MD3805222T2 (ro) 2015-01-30 2025-04-30 Oncoceutics Inc Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie
WO2016180843A1 (en) * 2015-05-13 2016-11-17 Boehringer Ingelheim International Gmbh New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors
CA3039012C (en) 2016-11-11 2021-08-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
JP6915907B2 (ja) * 2017-05-26 2021-08-04 江▲蘇▼新元素医▲薬▼科技有限公司Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. 尿酸排泄を促進するurat1阻害剤
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN111566101B (zh) * 2018-04-24 2023-08-11 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
SG11202109443QA (en) 2018-11-02 2021-09-29 Fount Bio Inc Crosslinked materials
WO2020160321A1 (en) * 2019-01-30 2020-08-06 Yale University Compounds, compositions, and methods for treating fibrosis
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
MX2021010669A (es) * 2019-03-07 2021-09-28 BioNTech SE Proceso para la preparacion de una imidazoquinolina sustituida.
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
BR112021020951A2 (pt) * 2019-04-19 2021-12-14 Fount Bio Inc Dispensação e retenção de agentes ativos dentro da pele
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク. 線維芽細胞増殖因子受容体キナーゼの阻害剤
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
WO2022166725A1 (zh) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856001B1 (en) * 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c receptor antagonists
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法

Also Published As

Publication number Publication date
KR20130132394A (ko) 2013-12-04
EA201201661A1 (ru) 2013-07-30
WO2012010704A1 (en) 2012-01-26
AP2012006640A0 (en) 2012-12-31
AU2011281504A1 (en) 2013-01-10
BR112013000107A2 (pt) 2016-05-17
CO6670575A2 (es) 2013-05-15
TW201217380A (en) 2012-05-01
EP2595987A1 (en) 2013-05-29
JP5991974B2 (ja) 2016-09-14
JP2013532652A (ja) 2013-08-19
MX2013000821A (es) 2013-05-30
CL2012003745A1 (es) 2013-05-31
PH12013500152A1 (en) 2013-02-18
UY33526A (es) 2012-02-29
EP2595987B1 (en) 2018-04-18
MA34389B1 (fr) 2013-07-03
CA2803467A1 (en) 2012-01-26
ECSP13012448A (es) 2013-03-28
US8735386B2 (en) 2014-05-27
SG187548A1 (en) 2013-03-28
CN103097388A (zh) 2013-05-08
GEP20156289B (en) 2015-05-25
US20120238542A1 (en) 2012-09-20
PE20131143A1 (es) 2013-10-23

Similar Documents

Publication Publication Date Title
AR084444A1 (es) Oxindolpirimidinas bencilicas y las preparaciones farmaceuticas que las contienen
AR073501A1 (es) Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR073700A1 (es) Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias
AR076134A1 (es) Derivados de 2,4 diaminopirimidinas
AR084443A1 (es) Triazolilfenil sulfonamidas, utiles como inhibidores de serina/treonina cinasa, y las preparaciones farmaceuticas que las contienen
DOP2010000272A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR078513A1 (es) Pirimidinas y composiciones farmaceuticas que las comprenden
AR106314A1 (es) COMPUESTOS DE ESPIRO[3H-INDOL-3,2’-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20160200A1 (es) Inhibidores de bromodominios
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
CU20090070A7 (es) Nuevos derivados de sulfonamida como antagonistas de la bradiquinina
AR075249A1 (es) Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles, metodo de preparacion de los mismos e intermediarios de dicha sintesis, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer, artritis, alergias y otras enfermedades.
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR076620A1 (es) 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO.
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
MX2022003023A (es) Compuestos heterociclicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure